Last reviewed · How we verify
LUNG-05: Investigating Chemotherapy Effectiveness for NSCLC Metastatic Patients
This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care Network (NCCN) treatment guidelines on dosage and scheduling for NSCLC FDA approved drugs.
Details
| Lead sponsor | University of Illinois at Chicago |
|---|---|
| Phase | NA |
| Status | RECRUITING |
| Enrolment | 29 |
| Start date | 2024-12-16 |
| Completion | 2026-09 |
Conditions
- NSCLC
Interventions
- Docetaxel
- Paclitaxel
- Gemcitabine
- Pemetrexed
- Vinorelbine
Primary outcomes
- To estimate the objective response rate (ORR) as measured by investigator assessment in patients with metastatic NSCLC treated with at least 2L of chemotherapy who have had OncoChoice-informed treatment — Every 6-8 weeks through study completion, an average of 2 years
The objective response rate is the proportion of all subjects with confirmed PR or CR according to investigator assessment, from the start of treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the start of treatment).
Countries
United States